Navigation Links
FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
Date:9/17/2007

f The Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the words "project," "believe," "anticipate," "plan," "expect," "estimate," "intend," "should," "would," "could," "will," "may" or other similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the results of clinical trials with respect to Sucampo Pharmaceuticals' products under development; the timing and success of submission, acceptance, review and approval of regulatory filings; Sucampo Pharmaceuticals' dependence on the commercial success of AMITIZA; Sucampo Pharmaceuticals' ability to obtain additional funding required to conduct its discovery, development and commercialization programs; Sucampo Pharmaceuticals' dependence on its co- marketing alliance with Takeda Pharmaceutical Company Limited; and Sucampo Pharmaceuticals' ability to obtain, maintain and enforce patent and other intellectual property protection for its discoveries. These and other risks are described in greater detail in the "Risk Factors" section of the Sucampo Pharmaceuticals' quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 22, 2007. Any forward-looking statements in this press release represent Sucampo Pharmaceuticals' views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Sucampo Pharmaceuticals anticipates that subsequent events and developments will cause its views to change. However, while Sucampo Pharmaceuticals may elect to update these forward-looking statements publicly at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise.

Contact:

Scott Solomon

Vice President

Sharon Merrill Associates, Inc.

Tel: 617-542-5300


'/>"/>
SOURCE Sucampo Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. UWM accepts resignation of research dean
2. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
3. Improve Recovery and Reproducibility with Pre-Treatment of Analytical TSK-GEL G3000SWXL Size Exclusion Columns
4. Quintessence cancer treatment chosen for clinical studies
5. ZyStor to exhibit cell disorder treatments
6. Radiology advance points way to non-invasive brain-cancer treatment
7. Animal testing: Beyond the protests, instances of mistreatment are rare
8. TomoTherapy leads the industry in CT image-guided treatments
9. Medical College getting $18.1 million to study radiation damage treatments
10. `Single-sales factor extends tax treatment to tech, service firms
11. Research on fruit flies opens up possibilities for human treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Boston, MA (PRWEB) August 21, 2014 ... collaboration company, has been recognized as one of ... 500 | 5000 magazine for the 2nd consecutive ... on its 33rd annual Inc. 500|5000, an exclusive ... list represents the most comprehensive look at the ...
(Date:8/20/2014)... history lessons often have it that American Indians largely ... chicken pox, influenza and tuberculosis brought to the New ... vary, about 20 million people lived in the Americas ... them were killed by European diseases., But new research ... University and Johannes Krause of the University of Tubingen ...
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group finds that the vascular ... Russia , India and ... 2013, roughly equal to the size of the United ... market will experience much faster growth as a result of strong ... Other key findings from Decision Resources Group,s coverage of the ...
(Date:8/20/2014)... SAN JOSE, Calif. , Aug. 20, 2014 ... UCSD highlights the transformative collaboration between the school,s ... (IoT).  As part of the Intel® Software Academic ... between computer sciences and the human body.  ... The study exhibits the work of ...
Breaking Biology Technology:SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2
... June 28, 2011 GeneTex, a leading manufacturer of ... that they will be launching a full line of ... as a model organism for scientific research. Due to their ... a useful model for genetic studies. Zebrafish eggs are ...
... While the health benefits of oregano oil is widely known ... from Global Healing Center is one of the most potent ... why it,s gaining popularity as a health supplement. ... 80% Carvacrol, a compound that is known scientifically for its ...
... 27, 2011 Metro Atlanta is building its reputation ... of Emory University and Children,s Healthcare of Atlanta, two ... million pediatric research facility. "Atlanta has a ... to continued medical advances that will benefit patients not ...
Cached Biology Technology:GeneTex Antibody Company to Launch a Line of New Zebrafish Primary Antibodies 2Organic Oregano Oil Gaining Popularity in Natural Health Field, According to Global Healing Center 2MAC Members Grow Atlanta's Bioscience Reputation 2MAC Members Grow Atlanta's Bioscience Reputation 3
(Date:8/20/2014)... John and Rebecca Moores Professor of Biology and Biochemistry at ... the International Society for the Study of the Origin of ... two from the U.S., one from France and one ... elected every three years, and 36 have been named since ... countries, the ISSOL includes researchers from disciplines as varied as ...
(Date:8/20/2014)... SALT LAKE CITY Researchers at Huntsman Cancer Institute (HCI) ... mutated forms of the gene that encodes BCR-ABL, the ... (CML). According to the American Cancer Society, nearly 6,000 ... , Drugs already in use, called tyrosine kinase inhibitors ... disease. They do not cure CML but control it ...
(Date:8/20/2014)... OTTAWA , Aug. 20, 2014 /CNW/ -  ... without warning and can quickly become life threatening for some ... As many as 1.2 million Canadians have food allergies and ... six per cent of children are estimated to have food ... range from mild skin irritations and hives to breathing difficulties ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2Blueprint for next generation of chronic myeloid leukemia treatment 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
... (March 9, 2009)Osteoplastya highly effective minimally invasive ... metastatic bone disease by injecting bone cement ... pain relief, often presenting individuals who are ... effect," according to researchers at the Society ...
... for strokes has taken a significant step forward today ... stroke-damaged brain tissue in rats. The team of ... Research Council (BBSRC) and led by Dr Mike Modo ... The work, carried out at the Institute of Psychiatry ...
... much less expensive means of making artemisinin, the most ... also help to extend the effectiveness of this drug. ... be done at far lower costs than extracting the ... tree, making microbial-based artemisinin a much cheaper but equally ...
Cached Biology News:Metastatic bone disease patients can walk in Lazarus' footsteps 2Metastatic bone disease patients can walk in Lazarus' footsteps 3Stem cells replace stroke-damaged tissue in rats 2Synthetic biology can help extend anti-malaria drug effectiveness 2Synthetic biology can help extend anti-malaria drug effectiveness 3Synthetic biology can help extend anti-malaria drug effectiveness 4
... Clone/PAD: ZMD.471. Immunogen: Synthetic peptide ... the mouse junctophilin-1. Specificity: Specific ... Mouse (positive controls: mouse brain and ... and skeletal muscle tissues). Applications: ...
Anti-human VEGFR-1/Flt-1, clone Flt-1/EWI, Monoclonal Antibody...
HSV 1 IgM...
... Printing Surface (3 glass slides coated with 100 /500/1000 ... wafer coated with 1000 Angstroms of Gold over TI ... (3 PDMS micropatterned stamps with series of 100 / ... or 200 um x 10 mm lines, 3 PDMS ...
Biology Products: